Posted by Michael Wonder on 01 Dec 2021
NICE terminates appraisal of new treatment for adolescents with obesity
1 December 2021 - NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in adolescents aged 12 to 17 years because Novo Nordisk did not provide an evidence submission.
As usual, NICE will review this decision if Novo Nordisk decides to make a submission.
